It was shown that not only thalidomide but also lenalidomide and pomalidomide bind to CRBN, attenuating the proliferation of myeloma cells through several pathways such as the down-regulation of autoubiquitination of CRBN [40–41]. Here, CRBN is linked to plasma cell myeloma.